Advertisement

Topics

Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin

2015-04-23 14:04:45 | BioPortfolio

Published on BioPortfolio: 2015-04-23T14:04:45-0400

Clinical Trials [95 Associated Clinical Trials listed on BioPortfolio]

The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patient...

Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection

OBJECTIVES: Assess the efficacy of a single infusion of a high titer pertussis immune globulin for the treatment of severe pertussis in children.

EUpertstrain 4 Study of Bordetella Pertussis Isolates

This study focus on the genetic changes of B. pertussis clinical isolates. For this panels of B. pertussis isolates has been collected during four periods in different European countries.

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Su...

Pertussis and Meningitis C Concomitant Vaccination in Adolescents

The trial includes groups receiving various combinations of meningitis C and pertussis containing vaccines, to be administered concomitantly in adolescents due their school leaving booster...

PubMed Articles [88 Associated PubMed Articles listed on BioPortfolio]

Resurgence of Pertussis and Emergence of the Ptxp3 Toxin Promoter Allele in South Italy.

Despite universal immunization programs, pertussis remains a major public health concern. This study aimed to describe the pertussis epidemiology in the Puglia region in 2006-2015 and to identify rece...

Identification of Etiologic Agents of the Pertussis-like Syndrome in Children by Real-time PCR Method.

The aim of this study was to recognize the identity and frequency of etiologic agents of the pertussis-like syndrome in children < 2 years of age. A cross-sectional hospital-based study conducted f...

A Population-Based Study of Recurrent Symptomatic Bordetella pertussis Infections in Children in California, 2010-2015.

Natural infection with Bordetella pertussis is thought to result in 4-20 years of immunity against subsequent symptomatic pertussis infection. However, these estimates are based on studies in unvaccin...

Effectiveness of parental cocooning as a vaccination strategy to prevent pertussis infection in infants: A case-control study.

During a pertussis epidemic in 2009, the Department of Health, Victoria, Australia, implemented a cocoon program offering parents of new babies a funded-dose of pertussis-containing vaccine. We assess...

Pertussis in California: A Tale of Two Epidemics.

California experienced pertussis epidemics in 2010 and 2014, with more than 9,000 and 11,000 reported cases, respectively. Using an ecologic study design, we compared age-specific pertussis incidence ...

Medical and Biotech [MESH] Definitions

A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)

One of the virulence factors produced by BORDETELLA PERTUSSIS. It is a multimeric protein composed of five subunits S1 - S5. S1 contains mono ADPribose transferase activity.

Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.

A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.

A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.

More From BioPortfolio on "Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial